Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2a study of ACE1831 in patients with IgG4-RD

Next Previous
X
Search
Trial Profile

A phase 1b/2a study of ACE1831 in patients with IgG4-RD

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACE 1831 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 22 Nov 2024 New trial record
    • 15 Nov 2024 According to an Acepodia media release, company has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the company's lead candidate ACE 1831 in IgG4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory autoimmune condition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top